Effects of Cyclosporine A on Pancreatic Insulin Secretion

Status Completed

Clinical Trial Summary

Our primary aim is to investigate if cyclosporine A reduces insulin secretion.

Clinical Trial Description

Our primary aim is to investigate if cyclosporine A may reduce insulin secretion by 20% or more. In order to get cyclosporine A naïve patients we will perform this investigation in dialysis patients on the waiting list for a renal transplantation. In addition we will investigate if also the peripheral insulin sensitivity and endothelia function is affected by cyclosporine A treatment in these patients. Since these patients will be treated with cyclosporine A we will also measure cyclosporine pharmacokinetics at the time of investigation and repeat this investigation at the time of the first week following transplantation in order to evaluate if a pretransplant cyclosporine dose can be of value in predefining the dose to be used at the time of transplantation. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00139035
Study type	Interventional
Source	University of Oslo School of Pharmacy
Contact
Status	Completed
Phase	Phase 4
Start date	April 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02565459` - MSC and Kidney Transplant Tolerance (Phase A)	Phase 1
Recruiting	`NCT02356419` - rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics	Phase 1
Recruiting	`NCT01876017` - Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure	Phase 1/Phase 2
Withdrawn	`NCT03019159` - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis	N/A
Completed	`NCT02047006` - Dose-finding of Rivaroxaban in Hemodialysis	Phase 4
Completed	`NCT01617824` - Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes	Phase 4
Completed	`NCT00597753` - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis	Phase 3
Completed	`NCT00828776` - Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure	Phase 2/Phase 3
Terminated	`NCT00372489` - Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD	Phase 2
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Completed	`NCT00228436` - Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients	Phase 2
Completed	`NCT03772171` - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting	`NCT02586402` - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis	Phase 2
Completed	`NCT01879618` - Use Of Fragmin In Hemodialysis	Phase 3
Not yet recruiting	`NCT01346215` - Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure	Phase 3
Completed	`NCT01220843` - FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease	Phase 3
Completed	`NCT01111630` - Study of Erythropoietin (EPO) Administration Schedule	Phase 4
Completed	`NCT00742716` - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease	Phase 2
Completed	`NCT00598273` - Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis	Phase 3
Completed	`NCT00597584` - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis	Phase 3